Princess Margaret Cancer Centre
Princess Margaret Cancer Centre
Toronto, Ontario, Canada22 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, gonadal disorder, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, squamous cell carcinoma, transitional cell carcinoma, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT04152499 | |
| AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas | gastroesophageal adenocarcinoma | Recruiting | Phase 2 | 2026-10-05 | NCT07290985 | |
| A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2026-10-01 | NCT07408063 | |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-10-01 | NCT02227251 | |
| Evaluation of Technological Innovation in Radiotherapy | cancer, injury, neoplasm, radiation injury | Recruiting | Not stated | 2026-09-01 | NCT03378856 | |
| Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 3 | 2026-07-29 | NCT01874353 | |
| Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, anal canal squamous cell carcinoma, cancer, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, metastatic malignant neoplasm, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Active, not recruiting | Not stated | 2026-07-14 | NCT03712566 | |
| Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-06-12 | NCT04566887 | |
| BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, cholangiocarcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, gastric cancer, gastric neoplasm, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2026-05-18 | NCT04421820 | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | Hemic and Lymphatic Diseases, Hypertrophy, Myeloproliferative Disorders, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Splenomegaly, anemia, blood platelet disease, bone marrow disorder, hematologic disorder, hemorrhagic disease, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-04-30 | NCT03165734 | |
| A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-04-17 | NCT06307795 | |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Neoplasms by Histologic Type, Tumor Virus Infections, diffuse large B-cell lymphoma, hematologic disorder, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm, non-Hodgkin lymphoma, viral infectious disease | Recruiting | Phase 1 | 2026-04-03 | NCT06208735 | |
| PET-MRI Esophagus Feasibility Study | Esophagogastric Cancer | Recruiting | Not applicable | 2026-03-05 | NCT05796102 | |
| Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer | Adnexal Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Not yet recruiting | Phase 3 | 2026-01-27 | NCT07286162 | |
| Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-01-07 | NCT04919811 | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | Adnexal Diseases, Disease Attributes, Disease Progression, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 3 | 2025-12-10 | NCT01844986 | |
| Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Recruiting | Phase 1 | 2025-12-08 | NCT05950802 | |
| Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma | B-cell neoplasm, Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2025-12-03 | NCT06485076 | |
| Comprehensive Health Assessment for my Cancer Treatment Plan | cancer, neoplasm | Active, not recruiting | Not applicable | 2025-11-28 | NCT05499975 | |
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2025-08-01 | NCT04675294 | |
| A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease | graft versus host disease, immune system disorder | Active, not recruiting | Phase 2 | 2025-06-22 | NCT05132166 | |
| Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | Phase 1 / Phase 2 | 2025-01-08 | NCT03715478 |